BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fabry Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Fabry Disease\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04020055-912@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT04020055)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and R
 enal Disease\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04020055
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05710692-10978@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT05710692)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: Study
  to Evaluate the Safety\, PK\, PD\, and Efficacy of PRX-102 in Japanese Pa
 tients With Fabry Disease\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pegunigalsidase-alfa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0571069
 2
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904261-912@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT06904261)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease an
 d Amenable GLA Variants\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06904261
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06328608-10978@assetmemo.bio
DTSTAMP:20261121T005420Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT06328608)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: A Stu
 dy to Learn About the Safety and Effects of the Study Drug PRX-102 in Chil
 dren and Adolescents With Fabry Disease\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegunigals
 idase-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06328608
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
